Posts

Biosimilars emerge as a potential next direct-to-employer drug strategy

on
A recent announcement points to a new direct-to-employer model for biosimilars: Waltz Health and Fresenius Kabi said employers, payers and PBMs will be able to access three biosimilars through Waltz Health’s platform, building on its direct-to-payer program for anti-obesity GLP-1 medicines. The products named are adalimumab-aacf, a Humira biosimilar; Otulfi (ustekinumab-aauz), a Stelara biosimilar; and Tyenne (tocilizumab-aazg), an Actemra biosimilar. The offer uses transparent, per-unit pricing. The broader employer trend is cost control: employers are increasingly steering members toward lower-cost biosimilars where clinically appropriate, while reassessing GLP-1 coverage and considering drug arrangements outside traditional PBM channels. Adoption still has room to grow. A CVS Caremark survey reported that 49% of employers encourage biosimilar substitution, while 40% are considering or exploring it. The same report cited more than $3.3 billion in gross Humira-related saving...

UniQure slides as four-year Huntington’s data show a weaker, statistically uncertain benefit

on

PhRMA names Eric Cantor as next chief

on

ai3Bio launches with $48M to target disease-driving immune cells

on

AstraZeneca invests $2 billion in Summit to advance ivonescimab–ADC combinations

on

Novo licenses Hengrui’s early-stage oral obesity candidate in potential $2.6B deal

on

U.S. details 0% tariff rules for specialty medicines

on

Merck licenses SciBrunch’s preclinical KRAS drug in deal worth up to $2.13B

on

Roche drops emugrobart obesity program and returns rights to Chugai

on

Mirum’s brelovitug meets Phase 3 primary endpoint in hepatitis delta

on

BARDA offers SCYNEXIS up to $214 million for antifungal SCY-247

on

Could bundled digital and IVD testing speed Alzheimer’s trial referrals?

on

Arvinas doses first patient in ARV-6723 Phase 1/2 trial

on